The average age of menopause remains constant despite drastic increases in global life expectancy; consequently, women are living longer in the post-menopausal state with increases in cardiovascular disease, osteoporosis, depression, and sexual dysfunction. In parallel, the average age of a woman’s first birth continues to rise, resulting in a shortened reproductive window and impaired fertility. The age at menopause is therefore of critical clinical and public health interest because of implications related to fertility, aging, and overall health. Age of menopause is related to all-cause mortality, and a major aging pathway (mTOR) may be a key link between reproductive and total lifespan. mTOR activity increases with age in multiple organs, and mTOR inhibitors promote longevity in animals. Importantly, the mTOR pathway regulates loss of egg cells from the ovary, and we showed in mice that mTOR inhibitors maintain egg cells and fertility during chemotherapy We propose to study the impact of mTOR inhibitors on reproductive lifespan and offspring health in mice, and to investigate the relationship between advancing age and mTOR in human ovaries. Our findings may have important therapeutic value for fertility and may lead to the development of useful clinical markers for aging and health.
|Effective start/end date||1/28/20 → 12/31/21|
- Friends of Prentice (Agmt 1/28/2020)